Sylvie Grégoire, James Mullen
Sylvie Grégoire has been elected to the board of PerkinElmer. She has more than 30 years of industry experience and most recently served for seven years as the president of human genetic therapies at Shire. Prior to that, she was executive chairwoman of IDM Pharma, currently a subsidiary of Takeda Pharmaceuticals. She also has been president and CEO of GlycoFi and held leadership, regulatory, and clinical research positions at Biogen and Merck. Grégoire is currently a board member of Galenica.
The firm also said that James Mullen has decided not to stand for re-election as a director of the company at the annual meeting of shareholders to be held on April 28, 2015.